Table 1.
Key model parameters used by Policy1-Bowel.
All costs are in 2018 Australian dollars (AUD).
Table 2.
Screening participation rate and diagnostic assessment compliance rate assumptions for all modelled scenarios.
Fig 1.
Estimated age-standardised rate (ASR) of (a) colorectal cancer incidence and (b) colorectal cancer mortality from 2006 to 2040 per 100,000 persons. Rates standardized to the 2001 Australian Standard Population.
Fig 2.
Estimated total number of incident colorectal cancer cases in the period 2020–2040 by stage.
For each scenario, the proportion of cases diagnosed at each stage is labelled in brackets.
Table 3.
Estimated colorectal cancer cases and deaths, number of colonoscopy assessments, colonoscopy-related adverse events, and direct program-related costsover the period 2020–2040 in the Australian population (number of cases, deaths, colonoscopies and adverse events rounded to nearest hundred).
Fig 3.
Estimated undiscounted costs to provide iFOBT screening, colonoscopy follow-up and surveillance, and colorectal cancer treatment in 2006–2040.
Table 4.
Estimated life-years, lifetime cost, and cost-effectiveness ratio (CER) vs current screening rates for a single birth cohort, as well as estimated thresholds for additional investment while remaining cost-effective (TCEI) for each scenario while remaining under willingness-to-pay thresholds of $10,000/LYS, $20,000/LYS, and $30,000/LYS.
The total TCEI for Australia is an annualized estimate for the 2020 population. All costs are in 2018 Australian dollars.